ABSTRACT Hepatocellular carcinoma (HCC) is the most prevalent primary hepatic cancer with high fatality and recurrence rates. The prognosis of advanced HCC is dismal, and treatment was limited for a decade to sorafenib with limited effectiveness and miserable overall survival. The advent of immune checkpoint inhibitors (ICPIs) provides a considerable step in the treatment of several advanced malignancies including HCC ...
إقراء المزيد